- Home
- GCT vs PHAR Comparison
GCT vs PHAR Comparison
Compare GCT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCT
- PHAR
- Stock Information
- Founded
- GCT 2019
- PHAR 1988
- Country
- GCT United States
- PHAR Netherlands
- Employees
- GCT N/A
- PHAR N/A
- Industry
- GCT Catalog/Specialty Distribution
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- GCT Consumer Discretionary
- PHAR Health Care
- Exchange
- GCT Nasdaq
- PHAR Nasdaq
- Market Cap
- GCT 798.3M
- PHAR 798.2M
- IPO Year
- GCT 2022
- PHAR N/A
- Fundamental
- Price
- GCT $31.03
- PHAR $13.70
- Analyst Decision
- GCT Buy
- PHAR Strong Buy
- Analyst Count
- GCT 2
- PHAR 3
- Target Price
- GCT $24.00
- PHAR $30.00
- AVG Volume (30 Days)
- GCT 1.2M
- PHAR 12.8K
- Earning Date
- GCT 08-07-2025
- PHAR 07-31-2025
- Dividend Yield
- GCT N/A
- PHAR N/A
- EPS Growth
- GCT 19.25
- PHAR N/A
- EPS
- GCT 3.31
- PHAR N/A
- Revenue
- GCT $1,193,610,000.00
- PHAR $339,836,000.00
- Revenue This Year
- GCT $1.98
- PHAR $12.88
- Revenue Next Year
- GCT $6.50
- PHAR $8.54
- P/E Ratio
- GCT $9.32
- PHAR N/A
- Revenue Growth
- GCT 21.20
- PHAR 22.44
- 52 Week Low
- GCT $11.17
- PHAR $6.73
- 52 Week High
- GCT $34.50
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- GCT 67.84
- PHAR 67.43
- Support Level
- GCT $29.79
- PHAR $12.13
- Resistance Level
- GCT $34.50
- PHAR $12.76
- Average True Range (ATR)
- GCT 1.75
- PHAR 0.89
- MACD
- GCT 0.16
- PHAR 0.13
- Stochastic Oscillator
- GCT 73.93
- PHAR 44.41
About GCT GigaCloud Technology Inc
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.